Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9158.123 | 0.9863 | 0.9687 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9158.123 | 0.7040 | 0.3404 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9158.123 | 0.7380 | 0.4144 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9158.123 | 0.6332 | 0.1876 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9158.123 | 0.5398 | -0.0100 | 0.8769 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9047.026 | 0.9241 | 0.7522 | 0.5972 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9047.026 | 0.8731 | 0.5934 | 0.5972 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9047.026 | 0.8963 | 0.6650 | 0.5972 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9047.026 | 0.9726 | 0.9090 | 0.5972 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9047.026 | 0.9465 | 0.8241 | 0.5972 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9047.026 | 0.7674 | 0.2837 | 0.5972 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9095.026 | 1.1812 | 1.3559 | 1.0168 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9095.026 | 1.2250 | 1.4418 | 1.0168 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9095.026 | 1.1851 | 1.3636 | 1.0168 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9095.026 | 1.1297 | 1.2549 | 1.0168 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9146.122 | 0.9832 | 0.9749 | 1.3408 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9146.122 | 1.0936 | 1.1381 | 1.3408 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9146.122 | 0.7730 | 0.6505 | 1.3408 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9146.122 | 0.7820 | 0.6649 | 1.3408 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9146.122 | 0.8250 | 0.7327 | 1.3408 | |
| AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9146.122 | 0.6801 | 0.5003 | 1.3408 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 5903.102 | 0.9945 | 0.9912 | 1.2557 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 5903.102 | 1.0224 | 1.0356 | 1.2557 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9163.026 | 0.6608 | -0.3398 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9163.026 | 0.8267 | 0.2022 | 0.3738 |